Walmart (WMT.N): Walmart's comparable sales in the U.S. are expected to be boosted by about 50 basis points from GLP-1 drugs in fiscal year 2027, while the boost is expected to be about 100 basis points in fiscal years 2025 and 2026.
2026-08-20
Walmart (WMT.N): Walmart's comparable sales in the U.S. are expected to be boosted by about 50 basis points from GLP-1 drugs in fiscal year 2027, while the boost is expected to be about 100 basis points in fiscal years 2025 and 2026.